Semaglutide vs Tirzepatide

What each option is approved to treat

Wegovy and Zepbound are the cited chronic weight-management products. Ozempic and Mounjaro are cited type 2 diabetes products. Semaglutide and tirzepatide differ in receptor activity, but the more useful first distinction is which exact FDA-approved product and indication match the clinical problem.

What direct comparative evidence found

SURPASS-2 compared tirzepatide with semaglutide 1 mg in adults with type 2 diabetes. At 40 weeks, mean body-weight change was -7.6 kg, -9.3 kg, and -11.2 kg across tirzepatide groups, compared with -5.7 kg with semaglutide. That is direct diabetes evidence, not a direct obesity trial.

The practical tradeoffs

Tirzepatide has the stronger weight-change result in SURPASS-2's diabetes population. Semaglutide has its own labeled products and evidence base. GI tolerance, diabetes regimen, eye history, pregnancy plans, oral medicines, route, access, and the approved indication can outweigh a single trial headline when choosing between them.

What separate obesity trials can answer

STEP 1 and SURMOUNT-1 support their own products in their own designs. They cannot create a direct obesity head-to-head claim.

Safety and interaction review

Contraindications, GI tolerance, eye history in diabetes, kidney-risk symptoms, oral medicines, pregnancy plans, and diabetes medicines can change the decision.

Use price after clinical clarity

Verified terms can help access planning, but must not imply that unlike formulations are clinically interchangeable.

What the cited sources establish

This comparison has one direct diabetes trial and separate obesity trials. SURPASS-2 compared tirzepatide with semaglutide 1 mg in type 2 diabetes; STEP 1 and SURMOUNT-1 each studied an obesity intervention in their own populations. Comparing their headlines as if they were one obesity head-to-head study would overstate the evidence.

The direct SURPASS-2 weight results favor tirzepatide in that type 2 diabetes study, but the decision still has several dimensions. Semaglutide may be discussed when its specific label and evidence fit the clinical goal; tirzepatide may be discussed when its specific label and evidence fit. The next useful comparison is the person's indication, diabetes regimen, GI tolerance, eye history, route preference, and ability to sustain follow-up.

The outcome comparison also depends on what is being measured. SURPASS-2 reports diabetes-trial weight change at 40 weeks, while STEP 1 and SURMOUNT-1 report separate obesity-trial outcomes at 68 and 72 weeks. A reader can use the direct trial to understand one diabetes comparison and the separate trials to understand each product's obesity evidence. Combining them into one leaderboard would hide the differences in dose, diagnosis, comparator, and study length.

Questions that change the next review

A pair-specific discussion should name the actual candidate products, then review indication, diabetes status, eye and GI history, other medicines, pregnancy plans, route, tolerability, and access. The key decision is not which molecule has the most dramatic average from an unrelated study design.

The direct-trial result is one input. The next decision turns on the diagnosis being treated, current diabetes medicines, eye and GI history, planned procedures, pregnancy plans, and route or access constraints.

Product details that still need verification

This page does not declare one medicine best for every reader or allow self-switching between products. It does not use a compounded formulation as a stand-in for an approved comparator. Any price or availability card is secondary to confirming the exact product and clinical fit.

SURPASS-2 is direct diabetes evidence, not a direct obesity trial. STEP 1 and SURMOUNT-1 should not be treated as a head-to-head contest. Safety, indication, history, access, and route matter. Compounded offers are not equivalent to approved products. Semaglutide is a GLP-1 receptor agonist and tirzepatide is a dual GIP/GLP-1 receptor agonist, but a treatment decision is not settled by mechanism or a headline result. The direct comparison cited here is in type 2 diabetes; obesity trials have different populations and designs. The next step is a clinician-led review of the exact product and your situation.

Use the current product label and prompt clinical care for urgent symptoms or medication changes.